Knochenspezifische Radium-223-Dichlorid-Therapie

详细信息    查看全文

• 作者：R. Tauber ; J. Gschwend ; K. Scheidhauer ; M. Eiber ; M. Krönke
• 关键词：SchlüsselwörterKnochenmetastasen ; Hormontherapie ; erweiterte ; Thrombozytopenien ; Kastrationsresistentes Prostatakarzinom ; Radionuklid ; Therapie ; Alphastrahler ; Therapie
• 刊名：Der Urologe
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：56
• 期：1
• 页码：24-31
• 全文大小：
• 刊物类别：Medicine
• 刊物主题：Urology;
• 出版者：Springer Medizin
• ISSN：1433-0563
• 卷排序：56

文摘

Radium-223 dichloride (Xofigo®, Alpharadin) is approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases. As a calcium mimetic, it is integrated into osteoplastic bone lesions and emits alpha particles with high energy which leads to local destruction of tumor cells. In the 2013 published ALSYMPCA trial, a significant advantage for overall survival and quality of life in comparison to placebo was found. Recent data suggest an increased potential in combination with next generation hormonal treatment.